PureTech Health PLC News - PRTC

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Annual and Transition Report (foreign Private Issuer) (20-f)

2022FY0001782999FalseInternational Financial Reporting StandardsNasdaqNasdaqFalsetrueP1YP3Y10.2500017829992022-0...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech Announces Annual Results for Year Ended December 31, 2022

Strong capital base with PureTech level cash, cash equivalents and short-term investments of $339.5 million1...

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

Financing will enable pivotal Phase 3 study of VE303 for recurrent C. difficile infection, to begin by 3Q 2023 Funds will also support Phase 2...

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

JAMA publication includes in-depth safety and efficacy results from Vedanta’s successful Phase 2 study of VE303 PureTech Health plc (Nasdaq:...

PureTech Health: Notice of Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K ...

PureTech to Present at the Barclays Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics...

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

Project to leverage vocal biomarkers for cognitive assessment of patients ages 55 and above in home environment PureTech Health plc (Nasdaq:...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

PureTech Health PLC (PRTC)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

PRTC News

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

PureTech Health: Notice of Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the Barclays Global Healthcare Conference

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

PRTC Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

PureTech Health PLC (PRTC) News

PureTech Health PLC (PRTC)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

PRTC News

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

PureTech Health: Notice of Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

PureTech to Present at the Barclays Global Healthcare Conference

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

PRTC Discussion

Your Recent History